USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS
Clinical trials have provided evidence for the efficacy of tocilizumab (TCZ) used alone and in combination with basic anti-inflammatory drugs in patients with rheumatoid arthritis (RA). TCZ therapy has been found to considerably alleviate the clinical manifestations of RA, improves joint function an...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2010-03-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/273 |
| Summary: | Clinical trials have provided evidence for the efficacy of tocilizumab (TCZ) used alone and in combination with basic anti-inflammatory drugs
in patients with rheumatoid arthritis (RA). TCZ therapy has been found to considerably alleviate the clinical manifestations of RA, improves
joint function and quality of life, and retards joint destruction and radiographic disease progression. TCZ has been noted to demonstrate good
results in the treatment of patients with the prolonged disease and a history of inefficient tumor necrosis factor-〈 inhibitors. |
|---|---|
| ISSN: | 1996-7012 2310-158X |